- Title: Subtitle
- S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
- Creators
- Mohamad Mohty - Hôpital Saint-AntoineMichael H. Tomasson - University of IowaBertrand Arnulf - Hôpital Saint-LouisNizar J Bahlis - University of CalgaryPaula Rodríguez-Otero - Clinica Universidad de NavarraJoaquín Martinez-Lopez - Hospital Universitario 12 De OctubreCyrille Touzeau - Centre Hospitalier Universitaire de NantesHang Quach - The University of MelbourneJulien Depaus - UCLouvainHisayuki Yokoyama - Tohoku UniversitySalomon Manier - Université de LilleNoopur Raje - Massachusetts General HospitalMarc S. Raab - University Hospital HeidelbergEmma Searle - The Christie HospitalEric Leip - Pfizer (United Kingdom)Sharon T. Sullivan - Pfizer (United Kingdom)Akos Czibere - Pfizer (United States)Andrea Viqueira - Pfizer (United Kingdom)Alexander Lesokhin - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- HemaSphere, Vol.7, pp.218-219
- DOI
- 10.1097/01.HS9.0000967696.13096.54
- PMCID
- PMC10428276
- ISSN
- 2572-9241
- eISSN
- 2572-9241
- Language
- English
- Date published
- 08/08/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health, Sport, and Human Physiology ; Internal Medicine
- Record Identifier
- 9984453215602771
Abstract
S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
HemaSphere, Vol.7, pp.218-219
08/08/2023
DOI: 10.1097/01.HS9.0000967696.13096.54
PMCID: PMC10428276
Details
Metrics
21 Record Views